We at CPP are thankful for our loyal members! It is because of you that we are able to provide such a great vaccine savings program and valuable educational resources to primary care providers across the country.
Despite the fact that many practices have received their flu shipments later in the season this year compared to prior years, CPP members have received 94% of all flu doses they reserved with Sanofi Pasteur to date. Depending on the presentation and quantity ordered by your practice, you may have seen more or less than this average.
CPP members who are also Sanofi Pasteur Fluzone Partners (flu reservations were confirmed by March 31, 2014), had the following shipping guarantees in place for all presentations except high dose for this flu season:
20% of reserve flu order by August 31, 2014
75% of reserve flu order by September 30, 2014
100% of reserve flu order by October 31, 2014
If these shipping commitments were not met for your practice, you may be eligible for credits to use towards future purchases for the 2015-2016 flu season. Please reach out to your Sanofi Pasteur representative during 2015-2016 pre-book period (January-March 2015) if you feel you are eligible for these credits.
Pediatric Care Online, the AAP’s online clinical resource, has received a facelift and the new site was launched in October. Check out www.pediatriccareonline.org to see the changes which includes combining the Red Book Online, Patient Education Online and Pediatric Care online into one tool!
Please remember CPP members receive free access to PCO as a member benefit. To sign-up your practice or for more information, contact the CPP office.
What professional resources do you use to stay current with recommendations, references, guides and industry best practices?
Click here to access the article.
In the last few weeks, we have seen price increase announcements on most of the routine vaccines you are providing to patients in your practice. While price increases are difficult for all parties to endure, here are some strategies you can employ to help minimize the negative impact to your practice’s bottom line:
- Join a buying group like CPP to access discounts on your vaccines.
- Make sure both your Sanofi Pasteur and Merck direct accounts are linked to the CPP contract to increase savings and maximize your CPP rebate potential.
- CPP members also enjoy an extended discount period during which Sanofi Pasteur and Merck vaccines can be purchased at pre-increase prices before the new prices take effect. Stock up on vaccines at the pre-increase price if you can!
- Notify your payers of the new prices as soon as possible. Most payers adjust their payment schedules quarterly. You can advocate for increased vaccine payment by referring insurance companies to the CDC Vaccine Price List for up to date private sector pricing.
Please also remember that the AAP put together a business case for providing vaccines in your practice. This tool should help guide you in making sure you are fairly compensated for the service you are providing your patients and the population in general.
Please click here to be taken to the article.
When is the last time you looked at your vaccine costs? Can you do better? Contact CPP for a free cost analysis to determine where savings opportunities might exist for your practice. Call 877-277-9330 or email email@example.com to get started!
On October 29, 2014, the U.S. Food and Drug Administration announced the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Of the 500 cases of meningococcal disease reported in the United States in 2012, 160 were caused by serogroup B, according to the U.S. Centers for Disease Control and Prevention.
While we are still awaiting an official recommendation of the ACIP and incorporation into the existing immunization schedule, prescribing information shows that the new vaccine is to be administered as a 3-dose series at months 0, 2 and 6 in the 10 through 25 year old age group.
Trumenba is manufactured by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania.